
Australia to Revise its Biosimilar Naming Conventions
Following a proposal by the World Health Organization, Australia will abandon a previously proposed update in biosimilar nomenclature.
Australia’s Therapeutic Goods Administration (TGA)
Australia’s original plan was to refer to biosimilars by their Australian Biological Name (ABN) followed by the prefix “sim(a),” where “(a)” was the three-letter code for the biosimilar assigned by WHO’s INN panel,
Different naming conventions have emerged in various countries for biosimilars released in the market. Some areas exclusively use a product’s INN, while others use the INN and a distinct nonproprietary identifier. “This variety of nomenclature approaches means that, at present, the same biological medicine can have different identifiers in different parts of the world,” WHO
Source:
RAPS
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.